a dual-incretin once-weekly injection
2.5 MG → 15 MG · 4-week vial supply

Tirzepatide is the most effective pharmacological weight-management compound ever to clear a phase-3 trial. It engages two appetite hormones, GLP-1 and GIP, rather than one, producing larger and more durable weight loss than any single-agonist GLP-1.
Tirzepatide is a synthetic peptide that simultaneously activates two receptors: GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide). The combined agonism slows gastric emptying, suppresses appetite via central pathways in the hypothalamus, improves insulin sensitivity, and reduces food noise. The dual mechanism is what produces the larger weight-loss effect compared with single-receptor GLP-1s like semaglutide.
| Week | Dose | Note |
|---|---|---|
| Weeks 01–04 | 2.5 mg / week | Initiation. Most people feel nothing or mild nausea. |
| Weeks 05–08 | 5.0 mg / week | Appetite suppression becomes noticeable. |
| Weeks 09–12 | 7.5 mg / week | First provider check-in. Re-evaluate fit. |
| Weeks 13–16 | 10.0 mg / week | Most patients hold here as the working dose. |
| Weeks 17+ | 12.5–15 mg / week | Therapeutic maximum, only if tolerated and clinically appropriate. |
Compounded tirzepatide plans start at $149/mo with the annual option. The price you see at checkout is the price billed. No insurance required.
Tirzepatide is the active molecule in branded Mounjaro and Zepbound. The HealthRX.com preparation is compounded by a licensed 503A pharmacy on a valid, patient-specific prescription. It is not the branded product.
In the SURMOUNT-1 trial, adults on the highest dose lost an average of 20.9% of body weight at 72 weeks. Individual results vary and depend on dose, tolerance, and lifestyle.
Tirzepatide activates two appetite hormones (GLP-1 and GIP), while semaglutide activates one (GLP-1). In trials tirzepatide produced larger average weight loss, though semaglutide has the longer track record and cardiovascular-outcomes data.
Tirzepatide is not appropriate for people with a personal or family history of medullary thyroid carcinoma or MEN-2, a history of severe pancreatitis, or during pregnancy or breastfeeding. A licensed clinician reviews your history before prescribing.
Researching your options? Explore the full GLP-1 medicine library or compare compounded semaglutide and compounded tirzepatide.